## Corporate Action Notice

November 21, 2017

## Ratio Change and Stock Distribution

## PT. Chandra Asri Petrochemical Tbk – Ratio Change and Stock Distribution

DR CUSIP: 69368N209 DR ISIN: US69368N2099 DR Ticker Symbol: PTCAY

Ratio (DS: Underlying Shares): 1: 50

Please be advised that PT. Chandra Asri Petrochemical Tbk has announced a five (5) for one (1) stock split on its ordinary common shares in the local market as of record date November 23, 2017. As a result, BNY Mellon will change the ratio on the PT. Chandra Asri Petrochemical Tbk Depositary Receipt ("DR") program. The ratio change will occur simultaneously with a 900% Depositary Share ("DS") distribution (a ten (10) for one (1) Split on the DRs).

First day of trading under the new ratio is expected to be December 04, 2017.

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for issuances and cancellations from the close of business November 21, 2017 and will reopen on December 6, 2017.

**BNY MELLON HAS ESTABLISHED THE** FOLLOWING DATES FOR THIS CORPORATE

**ACTION:** 

DR Record Date: Nov. 30, 2017 DR Payable Date: Dec. 01, 2017 **DR Distribution Rate:** 900% Issuance fee: \$0.02 per new DS

Old Ratio: 1 DS: 50 Ordinary Shares New Ratio: 1 DS: 25 Ordinary Shares

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

## **NEW YORK**

**LONDON** Ravi Davis Jacek Jankowski Richard J Maehr Vice President + 1 212 815 2267 + 44 207 163 7427 adrdesk@bnymellon.com jacek.jankowski@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\_upload\_file49220\_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.

